Product Information

XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK is a brand product labeled by Janssen Pharmaceuticals Inc., priced at $19.4545 per EA under NDC 50458058451. Its NADAC has been published 601 times since Feb 18, 2015.

FDA first approved this application on Jul 1, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the Rivaroxaban market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK

Rivaroxaban
$19.4545per EA
High Outlier

NDC

50458058451

Classification

Brand

Dosage Form

KIT

Effective Date

8/19/2026

Approval Type

New Drug (NDA)

FDA Application

NDA022406

FDA Approved

7/1/2011

TE Code

AB

On Market Since

9/16/2014

Price Statistics

The NADAC for XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK has been published 601 times since Feb 18, 2015, and over the history we have for it it has risen 89.0%. The table below summarizes its recorded NADAC range and movement.

Current price$19.4545 per EA
All-time high$19.5229 (Jun 10, 2026)
All-time low$10.0884 (Mar 18, 2015)
52-week high$19.5229
52-week low$19.0711
Median price$15.1162
Average price$15.1766
Largest weekly change+8.0% (Jan 10, 2018)
Weeks tracked601
Tracking sinceFeb 18, 2015

Price History

1W

-0.1%

1M

-0.1%

3M

-0.4%

6M

-0.4%

1Y

+1.9%

3Y

+12.2%

5Y

+23.8%

All

+89.0%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Rivaroxaban market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

No related drugs found.

Frequently asked questions

What is the NADAC price of XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK?

The current National Average Drug Acquisition Cost (NADAC) for XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK, manufactured by Janssen Pharmaceuticals Inc., is $19.4545 per EA (NDC 50458058451), effective Aug 19, 2026.

How has the price of XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK changed over time?

Over the history we have for it, the NADAC for XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK has risen 89.0%. It has been tracked across 601 weekly CMS publications since Feb 18, 2015.

What are the highest and lowest recorded NADAC prices for XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK?

Since Feb 18, 2015, the NADAC for XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK has ranged from a low of $10.0884 (Mar 18, 2015) to a high of $19.5229 (Jun 10, 2026), with a median of $15.1162 per EA.

Are there cheaper alternatives to XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK?

No other NADAC-published product currently shares the active ingredient and strength of XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK?

XARELTO DVT-PE TREATMENT 30-DAY STARTER 15-20 MG PACK (NDC 50458058451) is labeled by Janssen Pharmaceuticals Inc., and CMS classifies it as a brand product.